Tarlatamab, DLL3-targeted bispecific T-cell engager (7), received approval from the U.S. Food and Drug Administration (FDA) in 2024 for clinical application in the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) who experienced disease progression during or following platinum-based chemotherapy. Here, DLL3 is linked to small cell lung carcinoma.